Navigation Links
Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/29/2008

WALTHAM, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference being held at the Grand Hyatt Hotel in New York City. The company will present on Thursday, February 7, 2008, at 9:20 am (EST).

Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific, will provide an overview of the company and discuss its expectations for future financial performance.

You may listen to the presentation live on our Website, http://www.thermofisher.com, by clicking on "Investors." An audio archive of the Webcast will be available in that section of our Website under "Webcasts and Presentations" through Friday, March 7, 2008.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.

Media Contact Information:

Karen Kirkwood

Phone: 781-622-1306

E-mail: Karen.Kirkwood@thermofisher.com

Investor Contact Information:

Ken Apicerno

Phone: 781-622-1111

E-mail: ken.apicerno@thermofisher.com

Website: http://www.thermofisher.com


'/>"/>
SOURCE Thermo Fisher Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
2. Thermo Fisher Scientific to Present at Investor Conferences
3. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
4. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
5. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
6. Thermo Fisher Scientific to Present at Upcoming Investor Conferences
7. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
8. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
9. Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, October 25, 2007
10. Thermo Fisher Scientific Acquires Leader in Micro-Volume Spectrophotometers, NanoDrop Technologies
11. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):